

## Medicines Optimisation updates – [February 2023 / Issue 43]

- [Best Practice Guidance for Care homes](#)
- [Ozempic prescribing](#)
- [Urgent Field Safety Notice: FreeStyle LibreLink App for Android and FreeStyle Libre 3 App for Android \(all versions\)](#)
- [Celebrating Advanced Practice Conference 17th March 2023](#)
- [Shortages](#)
- [Medicines Supply Notification: Senokot® syrup and Senokot® 12 Years Plus syrup \(both containing 7.5mg/5ml sennosides\)](#)
- [NICE news February 2023](#)

## Best Practice Guidance for Care homes

A reminder that integrated Care Team have developed a number of Medicines Management Best Practice Guidance (BPG) for use within care homes across Kent and Medway.

These are available on the on EK, MS formularies, Medway Council Portal, DGS and WK Doris websites.

The Best practice guidance aims to support care home staff to deliver safe and effective medicines management to residents within care homes.

If you require any help or support, or have any questions please email the following address: [KMCCG.ICMOPharmacyteam@nhs.net](mailto:KMCCG.ICMOPharmacyteam@nhs.net)

### Links for BPG

East Kent: [Care home resources \(eastkentformulary.nhs.uk\)](http://eastkentformulary.nhs.uk)

DGS: <https://www.dgsdvhformulary.nhs.uk/kent-and-medway-guidance/miscellaneous/care-homes-best-practice-guidance/>

MS: [Care Home Best Practice Guidance \(medwayswaleformulary.co.uk\)](http://medwayswaleformulary.co.uk)

Medway council: <https://www.careportal.medway.gov.uk/Article/111170>

---

## Ozempic Prescribing

### **Ozempic® (Semaglutide Injections)- should be used for licensed indications only (management of type 2 diabetes)**

Due to a national shortage with Ozempic® (Semaglutide) it is important that prescribing is in line with licenced indications only – for the treatment of adults

with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

We would like to advise practices that Ozempic® (Semaglutide 0.25mg/0.19ml, 0.5mg/0.37ml and 1mg/0.74ml solution for injection) should not be prescribed for any other indication apart from its licensed use and in line with national and local guidelines in the management of type 2 diabetes. We are aware of increased requests to prescribe this medication solely for weight loss due to various reasons such as social media, however, this request is **off-label**. Ozempic® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise only.

These recommendations are pertinent as there is currently a national shortage of Ozempic®. The DHSC memo advises that:

Clinicians in primary and secondary care should:

- ensure that Ozempic® is being used for licensed indications only.
- not initiate new patients on Ozempic® until full supplies become available in January 2024
- work with local pharmacy teams to understand availability of Ozempic®. Please see advice below if Ozempic® is unavailable and patient does not have sufficient supplies.

For more information on the shortage and alternatives, please see Medicine Supply Notification MSN/2022/080 [here](#).

For any further queries regarding supply issues please contact [DHSCmedicinesupplyteam@dhsc.gov.uk](mailto:DHSCmedicinesupplyteam@dhsc.gov.uk)

Any requests from patients or other health care professionals to prescribe outside of licensed indications should be referred back to the healthcare professional requesting it or the patient should be advised that the medication is not licensed for weight loss and cannot be prescribed for this reason.

## Urgent Field Safety Notice: FreeStyle LibreLink App for Android and FreeStyle Libre 3 App for Android (all versions)

February 2023

**Please see the attached document below for important information from the manufacturer, Abbott, regarding an Urgent Field Safety Notice**

**Product:** FreeStyle LibreLink App for Android and FreeStyle Libre 3 App for Android (all versions)

**Reference:** ADC FA1010-2023

Abbott is working on updates to resolve the issue



Baseline, ADC  
FA1010-2023\_FSLL\_F

[issue-43-baseline-adc.pdf \(medwayswaleformulary.co.uk\)](https://medwayswaleformulary.co.uk/issue-43-baseline-adc.pdf)

---

## Celebrating Advanced Practice Conference 17th March 2023

Kent & Medway Advanced Practice Forum and Kent & Medway Training Hub wants to celebrate Advancing Practice across our Integrated Care System.

We would like to invite you to the Advancing Practice Conference on Friday 17<sup>th</sup> March @ Ashford International Hotel 9am – 5pm

Places are limited so please reserve your place via [Eventbrite link](#) or copy this link <http://bit.ly/3Bt4aJu> in your browser to book your place at this event.



ACP Conference  
Agenda 2023.pdf

[ACP Conference Agenda 2023 \(medwayswaleformulary.co.uk\)](https://medwayswaleformulary.co.uk/ACP-Conference-Agenda-2023.pdf)

## Shortages

Please find attached the medicines shortages update (16<sup>th</sup> February 2023).

Practices are encouraged to register for access to the SPS website

<https://www.sps.nhs.uk/> and access the full medicines supply tool directly in real time.



Shortages summary  
Feb 23.docx

[issue-43-shortages-summary-feb-23.pdf \(medwayswaleformulary.co.uk\)](https://www.medwayswaleformulary.co.uk/issue-43-shortages-summary-feb-23.pdf)

---

## Medicines Supply Notification: Senokot® syrup and Senokot® 12 Years Plus syrup (both containing 7.5mg/5ml sennosides)

Issued on 23.01.2023

Please see a Tier 2 medicine supply notification embedded below. The status according to [SPS Medicines Supply Tool](#) is, supply returning with anticipated date of re-supply updated to 10<sup>th</sup> March 2023.



MSN\_2023\_004  
Senokot® syrup and

[issue-43-msn\\_2023\\_004-senokot-syrup-and-senokot-12-years-plus-syrup-both-containing-75mg-per-5ml-sennosides.pdf \(medwayswaleformulary.co.uk\)](https://www.medwayswaleformulary.co.uk/issue-43-msn_2023_004-senokot-syrup-and-senokot-12-years-plus-syrup-both-containing-75mg-per-5ml-sennosides.pdf)

---

## NICE News

Please see below NICE news for February 2023



NICE news Feb  
23.docx

[nice-news-feb-22.pdf \(medwayswaleformulary.co.uk\)](https://www.medwayswaleformulary.co.uk/nice-news-feb-22.pdf)

*Every effort is made to ensure that the information contained in this newsletter is accurate and up to date at the time of publication. Please be aware that information about medicines and therapeutics will change over time, and that information may not be current after the initial date of publication. Please take note of the publication date and seek further advice if in any doubt about the accuracy of the information.* The information contained in this newsletter is the best available from the resources at our disposal at the time. Acronyms used are standard formulary. This newsletter is produced by the NHS Kent and Medway Medicines Optimisation Team on behalf of the Kent & Medway ICB. For all correspondence including any queries, please contact the Medicines Optimisation team email: [kmicb.medicinesoptimisation@nhs.net](mailto:kmicb.medicinesoptimisation@nhs.net)